Neumora Therapeutics (NMRA) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 49.5% versus a loss of 85.7%. Neumora Therapeutics is the larger company by market cap ($63.0 million vs $56.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMRA | OKYO |
|---|---|---|
| Share price | $0.3339 | $1.07 |
| Market cap | $63.01M | $56.15M |
| 1-day change | -3.78% | -7.76% |
| YTD return | -81.35% | -48.31% |
| 1-year return | -85.67% | -49.53% |
| EPS (TTM) | $-1.06 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-236.93M | $-4.71M |
| 52-week high | $3.65 | $3.20 |
| 52-week low | $0.301 | $1.00 |
| Distance from 52-week high | -90.85% | -66.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1696.95% | +678.50% |
| Average volume | 1.69M | 143.41K |
| Shares outstanding | 188.69M | 52.48M |
| Employees | 63 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed NMRA by 36.1 percentage points over the past year.
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
NMRA vs OKYO FAQ
Which is bigger, Neumora Therapeutics or OKYO Pharma?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $63.01M compared with $56.15M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, NMRA or OKYO?
OKYO returned -49.53% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Neumora Therapeutics and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.